Axon Enterprise, Inc $AXON Shares Bought by Amalgamated Bank

Amalgamated Bank lifted its position in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 5.9% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 16,337 shares of the biotechnology company’s stock after buying an additional 908 shares during the quarter. Amalgamated Bank’s holdings in Axon Enterprise were worth $13,526,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of AXON. Brighton Jones LLC purchased a new stake in shares of Axon Enterprise during the fourth quarter worth about $480,000. Vontobel Holding Ltd. grew its holdings in shares of Axon Enterprise by 73.8% during the first quarter. Vontobel Holding Ltd. now owns 6,736 shares of the biotechnology company’s stock worth $3,543,000 after buying an additional 2,860 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd grew its holdings in shares of Axon Enterprise by 1.7% during the first quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 8,337 shares of the biotechnology company’s stock worth $4,385,000 after buying an additional 137 shares in the last quarter. Summit Trail Advisors LLC grew its holdings in shares of Axon Enterprise by 17.1% during the first quarter. Summit Trail Advisors LLC now owns 554 shares of the biotechnology company’s stock worth $291,000 after buying an additional 81 shares in the last quarter. Finally, DAVENPORT & Co LLC grew its holdings in shares of Axon Enterprise by 5.1% during the first quarter. DAVENPORT & Co LLC now owns 940 shares of the biotechnology company’s stock worth $494,000 after buying an additional 46 shares in the last quarter. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on AXON. Piper Sandler initiated coverage on shares of Axon Enterprise in a report on Tuesday, September 23rd. They set an “overweight” rating and a $893.00 price target for the company. JPMorgan Chase & Co. lifted their price target on Axon Enterprise from $730.00 to $850.00 and gave the company an “overweight” rating in a report on Thursday, July 17th. Zacks Research downgraded shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 2nd. Weiss Ratings restated a “hold (c)” rating on shares of Axon Enterprise in a report on Wednesday, October 8th. Finally, Needham & Company LLC restated a “buy” rating and issued a $870.00 target price on shares of Axon Enterprise in a report on Wednesday, September 24th. Fourteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, Axon Enterprise has a consensus rating of “Moderate Buy” and an average price target of $841.64.

Axon Enterprise Price Performance

Axon Enterprise stock opened at $738.88 on Friday. Axon Enterprise, Inc has a 1 year low of $422.38 and a 1 year high of $885.91. The firm has a 50 day moving average price of $731.73 and a 200 day moving average price of $730.58. The company has a market cap of $58.01 billion, a price-to-earnings ratio of 182.44, a PEG ratio of 29.49 and a beta of 1.41. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.58. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The company had revenue of $668.54 million during the quarter, compared to the consensus estimate of $641.77 million. During the same period in the previous year, the firm earned $1.20 earnings per share. Axon Enterprise’s revenue for the quarter was up 32.6% on a year-over-year basis. Axon Enterprise has set its FY 2025 guidance at EPS. Sell-side analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, President Joshua Isner sold 15,919 shares of the business’s stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $746.26, for a total transaction of $11,879,712.94. Following the completion of the sale, the president directly owned 238,379 shares in the company, valued at $177,892,712.54. The trade was a 6.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Brittany Bagley sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $713.88, for a total transaction of $3,569,400.00. Following the sale, the chief financial officer owned 93,592 shares of the company’s stock, valued at approximately $66,813,456.96. This represents a 5.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 59,932 shares of company stock valued at $45,115,616 over the last quarter. Company insiders own 4.40% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.